Pathways of Immune Evasion in Acute Myeloid Leukemia
Pathways of Immune Evasion in Acute Myeloid Leukemia
批准号:
10444630
负责人:
Evan Ferguson Lind
金额:
$34.96万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-03-18 至 2027-02-28
关键词:
Acute Myelocytic LeukemiaAdaptive Immune SystemAffectAmino Acid MotifsAnimal ModelAntibodiesAspirate substanceBehaviorBiologyBloodBone MarrowBromodomainCell Differentiation processCell SurvivalCell physiologyCellsCessation of lifeChromatinChromatin StructureChronicDNA MethylationDNA Methyltransferase InhibitorDNA Modification MethylasesDataDevelopmentDiagnosisDiseaseDrug TargetingDrug usageEpigenetic ProcessFamily memberFunctional disorderFutureGenetic TranscriptionGenetically Engineered MouseGoalsHematopoietic NeoplasmsHumanImmuneImmune EvasionImmune TargetingImmune systemImmunosuppressionImmunotherapyImpairmentIn VitroLaboratoriesLeukemic CellLiteratureLymphoidMEKsMalignant NeoplasmsMitogen-Activated Protein KinasesMutationMyelogenousPathway interactionsPatientsPharmaceutical PreparationsPhenotypePopulationPrognosisPropertyProtein MethyltransferasesPublishingReaderRoleSamplingSignal PathwaySignal TransductionT cell regulationT-Cell ProliferationT-LymphocyteT-Lymphocyte SubsetsTestingTherapeuticTimeWorkadult leukemiabasecancer cellcancer typecell transformationcell typecytokineepigenomeexhaustexhaustionexperimental studyfunctional disabilityimmune checkpointimmune checkpoint blockadeimmune clearanceimmune functionin vivoinhibitorleukemiamouse modelneoplastic cellnovelprecursor cellprogramsprotein functionrational designresponsesmall moleculetargeted treatmenttranscription factortumortumor microenvironmenttumor-immune system interactions
中文摘要
项目总结/摘要
急性髓系白血病(AML)是最常见的成人白血病,并且具有非常差的预后;
被诊断为AML的患者会死于这种疾病。AML是由恶性淋巴细胞的不受控制的增殖引起的。
分化的髓样前体细胞。免疫疗法,包括检查点阻断,目前正在
在AML的背景下进行研究。我们以前的工作已经确定,T细胞的百分比存在于
诊断时AML患者的骨髓与总生存期相关,提供了证据
适应性免疫系统,特别是T细胞,能够识别恶性细胞。我们的实验室和
其他人已经表明AML通过抑制T细胞功能来逃避免疫系统的攻击。值得注意的是,
这种功能性抑制在大多数情况下可以通过免疫检查点分子阻断在体外逆转。
以前的文献已经证明,免疫系统的衰竭状态可以由免疫系统的免疫缺陷引起。
表观遗传程序在慢性刺激后赋予T细胞。我们之前已经展示了地图的作用
激酶途径(MAPK)在维持AML中存在的T细胞中的这种耗尽状态中的作用。将细胞转化为
AML由影响增殖、分化和表观遗传状态的突变组合引起。为此
因此,靶向信号传导和表观遗传状态的药物已被批准或正在积极研究,
AML的治疗。
对于这个项目,我们的长期目标是更好地了解功能性T细胞耗竭
及其在AML中的相关性。我们的近期目标是研究MAPK通路,DNA甲基转移酶,
和表观遗传阅读器BET蛋白在AML背景下T细胞耗竭中的作用。我们会进行这些研究
核心假设是,AML中通过T细胞耗竭的免疫逃避是由信号通路引起的,
例如T细胞中的MEK和表观遗传状态,并且在AML中靶向这些途径将逆转免疫
镇压为了实现这一目标,我们提出了以下三个目标:1)了解MAPK的作用
AML中T细胞的功能。这将包括T细胞的机制研究,但也研究肿瘤和
AML免疫微环境中的其他淋巴样和髓样群体。2)的影响进行评估
表观遗传途径对AML小鼠模型中T细胞免疫功能的影响。根据我们初步的
数据,我们将专注于DNA甲基化和BET蛋白质功能。3)定义细胞和免疫途径
在人AML的肿瘤微环境中的抑制。我们将研究与T细胞相关的细胞类型,
患者样本中的抑制。我们还将研究MEK、BET和DNMT抑制剂对患者样本的影响。
这些实验将使我们更好地了解AML中T细胞耗竭的生物学
疾病重要的是,这些研究的结果将对这种致命疾病的治疗产生影响,
合理设计联合小分子和免疫靶向治疗。
英文摘要
Project Summary/Abstract
Acute Myeloid Leukemia (AML) is the most common adult leukemia and has a very poor prognosis; most
patients diagnosed with AML will die from this disease. AML results from uncontrolled proliferation of poorly
differentiated myeloid precursor cells. Immune therapies, including checkpoint blockade, are currently being
studied in the context of AML. Our previous work has established that the percentage of T cells present in the
bone marrow of patients with AML at the time of diagnosis correlates with overall survival, providing evidence
that the adaptive immune system, and specifically T cells, are able to recognize malignant cells. Our lab and
others have shown that AML evades attack by the immune system by suppressing T cell function. Significantly,
this functional suppression can be reversed in vitro in most cases by immune checkpoint molecule blockade.
Previous literature has demonstrated that the exhausted state of the immune system can result from an
epigenetic program imparted on T cells after chronic stimulation. We have previously shown a role for the map
kinase pathway (MAPK) in maintaining this exhausted state in T cells present in AML. Transformation of cells to
AML results from a combination of mutations affecting proliferation, differentiation and epigenetic state. For this
reason, drugs targeting signaling and epigenetic state are approved or are being actively studied for the
treatment of AML.
For this project, our long-term goals are to provide a better understanding of functional T cell exhaustion
and its relevance in AML. Our immediate goal is to study the role of the MAPK pathway, DNA methyltransferases
and the epigenetic reader BET proteins in T cell exhaustion in the context of AML. We will conduct these studies
with the central hypothesis that immune evasion via T cell exhaustion in AML is imparted by signaling pathways
such as MEK and epigenetic states in T cells and that targeting these pathways in AML will reverse immune
suppression. To accomplish this goal, we propose the following three aims: 1) Understand the role of the MAPK
pathway on T cell function in AML. This will consist of mechanistic studies in T cells, but also study tumor and
other lymphoid and myeloid populations in the immune microenvironment of AML. 2) Assess the impact of
epigenetic pathways on the immunological function of T cells in mouse models of AML. Based on our preliminary
data we will focus on DNA methylation and BET protein function. 3) Define cells and pathways of immune
suppression in the tumor microenvironment of human AML. We will study a cell type associated with T cell
suppression in patient samples. We will also study effects of MEK, BET and DNMT inhibitors on patient samples.
Together these experiments will give us a better understanding of the biology of T cell exhaustion in AML
disease. Importantly, results from these studies will have impact on treatment of this lethal disease by allowing
rational design of combined small molecule and immune targeted therapies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Pathways of Immune Evasion in Acute Myeloid Leukemia
-
批准号:10594502
-
项目类别:
-
资助金额:$34.26万
-
财政年份:2022
-
负责人:Evan Ferguson Lind
-
依托单位:
海外基金